Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 27, 2026 (before its estimated June 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanised monoclonal antibody injection in healthy Chinese subjects (Part A) and subjects with acute gout flare (Part B)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-16.
Status change: Recruiting → Active, Not Recruiting 2026-05-25
Trial Details
NCT Number NCT07295496
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Acute Gout Flare
Enrollment 64 participants
Start Date 2025-12-08
Primary Completion 2026-06-07 (estimated)
Study Completion 2026-06-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-27